4.8 Article

Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy

Journal

NATURE COMMUNICATIONS
Volume 8, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms15480

Keywords

-

Funding

  1. National Plan for Scientific Research, Development and Technological Innovation [PI12/00552, PI15/00860]
  2. Instituto de Salud Carlos III (ISCIII)
  3. Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases by European Development Regional Fund ERDF 'A way to achieve Europe' [REIPI RD12/0015/0014, REIPI RD16/0016/0006]
  4. program 'Innova Saude' by SERGAS-Galician Healthcare Service
  5. PhD scholarship from Portugal [SFRH/BD/64740/2009]
  6. POPH/FSE
  7. Spanish Network for Research in Infectious Diseases [REIPI RD12/0015/0014, RD16/ 0016/0006]
  8. Miguel Servet Programme [CP13/00226]
  9. Galician Plan for Research, Innovation and Growth (I2C Plan)

Ask authors/readers for more resources

Vaccine development is a priority for global health due to the growing multidrug resistance in bacteria. D-glutamate synthesis is essential for bacterial cell wall formation. Here we present a strategy for generating effective bacterial whole-cell vaccines auxotrophic for D-glutamate. We apply this strategy to generate D-glutamate auxotrophic vaccines for three major pathogens, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus. These bacterial vaccines show virulence attenuation and self-limited growth in mice, and elicit functional and cross-reactive antibodies, and cellular immunity. These responses correlate with protection against acute lethal infection with other strains of the same species, including multidrug resistant, virulent and/or high-risk clones such as A. baumannii AbH12O-A2 and Ab307-0294, P. aeruginosa PA14, and community-acquired methicillin-resistant S. aureus USA300LAC. This approach can potentially be applied for the development of live-attenuated vaccines for virtually any other bacterial pathogens, and does not require the identification of virulence determinants, which are often pathogen-specific.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available